Listar por tema "Sodium-Glucose Transporter 2 Inhibitors"

Mostrando ítems 1-1 de 1

SGLT-2 inhibitors for people with type 2 diabetes.

Málaga Rodríguez, Germán Javier; Ruiz, Eloy F. (Elsevier, 2019)

Evidence that sodium-glucose co-transporter-2 inhibitors (SGLT2i) can reduce cardiovascular risk—with trials showing reductions in cardiovascular death, myocardial infarction, and stroke—would suggest they have much to ...